AU2004275444A1 - Method of inhibiting the expression of a multi-drug resistance genes and inhibiting the production of proteins resulting from the expression of such genes thereby enhancing the effectiveness of chemotherapeutic agents to treat cancers - Google Patents

Method of inhibiting the expression of a multi-drug resistance genes and inhibiting the production of proteins resulting from the expression of such genes thereby enhancing the effectiveness of chemotherapeutic agents to treat cancers Download PDF

Info

Publication number
AU2004275444A1
AU2004275444A1 AU2004275444A AU2004275444A AU2004275444A1 AU 2004275444 A1 AU2004275444 A1 AU 2004275444A1 AU 2004275444 A AU2004275444 A AU 2004275444A AU 2004275444 A AU2004275444 A AU 2004275444A AU 2004275444 A1 AU2004275444 A1 AU 2004275444A1
Authority
AU
Australia
Prior art keywords
cholesterol absorption
phenyl
absorption inhibitor
group
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004275444A
Other languages
English (en)
Inventor
Tatjana Lukic
Kristina Sachs-Barrable
David John Stewart
Kishor M. Wasan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forbes Medi-Tech Inc
Original Assignee
Forbes Medi-Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forbes Medi-Tech Inc filed Critical Forbes Medi-Tech Inc
Publication of AU2004275444A1 publication Critical patent/AU2004275444A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
AU2004275444A 2003-09-26 2004-09-27 Method of inhibiting the expression of a multi-drug resistance genes and inhibiting the production of proteins resulting from the expression of such genes thereby enhancing the effectiveness of chemotherapeutic agents to treat cancers Abandoned AU2004275444A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67305103A 2003-09-26 2003-09-26
US10/673,051 2003-09-26
PCT/CA2004/001697 WO2005030225A2 (fr) 2003-09-26 2004-09-27 Methode destinee a inhiber l'expression de genes de multiresistance aux medicaments et a inhiber la production de proteines resultant de l'expression de ces genes en vue d'ameliorer l'efficacite d'agents chimiotherapeutiques pour le traitement des cancers

Publications (1)

Publication Number Publication Date
AU2004275444A1 true AU2004275444A1 (en) 2005-04-07

Family

ID=34393484

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004275444A Abandoned AU2004275444A1 (en) 2003-09-26 2004-09-27 Method of inhibiting the expression of a multi-drug resistance genes and inhibiting the production of proteins resulting from the expression of such genes thereby enhancing the effectiveness of chemotherapeutic agents to treat cancers

Country Status (9)

Country Link
EP (1) EP1677803A2 (fr)
JP (1) JP2007524651A (fr)
KR (1) KR20060135615A (fr)
CN (1) CN1874780A (fr)
AU (1) AU2004275444A1 (fr)
BR (1) BRPI0414812A (fr)
CA (1) CA2540364A1 (fr)
RU (1) RU2006114049A (fr)
WO (1) WO2005030225A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2337727T3 (es) 2005-06-20 2010-04-28 Schering Corporation Derivados de piperidina utiles como antagonistas de histamina h3.
JP2011517555A (ja) * 2008-03-14 2011-06-16 ジェネンテック， インコーポレイテッド 薬剤耐性に関連する遺伝的変異
CN102552284A (zh) * 2011-12-13 2012-07-11 陕西师范大学 麦角甾醇在制备肿瘤多药耐药逆转药物中的应用
EP3110429A4 (fr) 2014-02-27 2018-02-21 Lycera Corporation Thérapie cellulaire adoptive utilisant un agoniste du récepteur gamma orphelin associé au récepteur de l'acide rétinoïque et méthodes thérapeutiques associées
JP6728061B2 (ja) 2014-05-05 2020-07-22 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγアゴニストとして用いるテトラヒドロキノリンスルホンアミド及び関連化合物ならびに疾患の治療
CA2982847A1 (fr) 2015-05-05 2016-11-10 Lycera Corporation Sulfonamides de dihydro-2h-benzo[b][1,4]oxazine et composes apparentes destines a etre utilises comme agonistes de ror.gamma. et pour le traitement de maladies
US10611740B2 (en) 2015-06-11 2020-04-07 Lycera Corporation Aryl dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
CN106420768B (zh) * 2015-08-13 2018-12-28 广州中医药大学第二附属医院 赪酮甾醇作为p-糖蛋白抑制剂的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995017192A1 (fr) * 1993-12-22 1995-06-29 The Salk Institute For Biological Studies Procede permettant de reduire la resistance multiple aux anti-cancereux
EP1285914B1 (fr) * 2001-08-13 2007-12-19 PheneX Pharmaceuticals AG Ligands du récepteur nucéaire nr1h4
DE60334711D1 (de) * 2002-07-30 2010-12-09 Karykion Inc Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumoren

Also Published As

Publication number Publication date
WO2005030225A3 (fr) 2005-05-26
CA2540364A1 (fr) 2005-04-07
BRPI0414812A (pt) 2006-11-14
CN1874780A (zh) 2006-12-06
JP2007524651A (ja) 2007-08-30
KR20060135615A (ko) 2006-12-29
RU2006114049A (ru) 2007-11-20
EP1677803A2 (fr) 2006-07-12
WO2005030225A2 (fr) 2005-04-07

Similar Documents

Publication Publication Date Title
WO2005042692A2 (fr) Methode permettant d'inhiber l'expression de genes qui induisent l'influx de cholesterol cellulaire dans les cellules animales et d'inhiber la production de proteines issues de l'expression de ces genes
CA2968145C (fr) Analogues d'ether phospholipidique utilises en tant que vehicules de medicament ciblant le cancer
EP2744773B1 (fr) Composés d'éthers de bisphénol fluorés et leurs procédés d'utilisation
EP3426348B1 (fr) Dérivé de 3-désoxy et compositions pharmaceutiques associées
KR20090082284A (ko) Ｂｃｌ 단백질과 결합 파트너와의 상호작용을 억제하는 화합물 및 방법
JP2003508539A (ja) 肝臓に特異的なドラッグデリバリーのためのプロドラッグ
WO2008098351A1 (fr) Traitement de maladies prolifératives médiées par la d-cycline et de malignités hématologiques
WO2016028225A1 (fr) Complexes de platine en tant qu'agents anticancéreux
AU2004275444A1 (en) Method of inhibiting the expression of a multi-drug resistance genes and inhibiting the production of proteins resulting from the expression of such genes thereby enhancing the effectiveness of chemotherapeutic agents to treat cancers
EP2906564A1 (fr) Traitement du cancer du cerveau à l'aide d'agélastatine a (aa) et d'analogues de celle-ci
EP2890374B1 (fr) Compositions et procédés de sensibilisation aux médicaments ou d'inhibition d'une cellule cancéreuse
CN113056474A (zh) 用于治疗纤维化、nash和nafld的方法中的雷公藤内酯及其前药
WO2016077346A1 (fr) Procédés de traitement du cancer de la vessie avec le ciclopirox, le ciclopirox olamine ou un promédicament à base de ciclopirox
US9399644B2 (en) [1,3] dioxolo [4,5-G] quinoline-6(5H)thione derivatives as inhibitors of the late SV40 factor (LSF) for use in treating cancer
WO2014048313A1 (fr) Produit de condensation de dérivé théanine et de dérivé coumarine d'acide carboxylique, intermédiaire du produit de condensation, leur procédé de préparation, et leur utilisation
EP3813846B1 (fr) Compositions et procédés pour le diagnostic, le traitement et la prévention de troubles néoplasiques et neurologiques
EP2699580B1 (fr) Analogues de diazonamide
EP3403661B1 (fr) Extrait dérivé d'un organisme marin, composé, et composition à visée médicale ayant une activité de suppression de formation de niches dans les cellules souches leucémiques
RUSSO SPENA Pin1 protein: a druggable target in high grade serous ovarian cancer
AU2018201003A1 (en) 6-substituted estradiol derivatives for the treatment of alzheimer's disease
ES2390303A1 (es) Compuestos y composiciones para el tratamiento de mieloma múltiple.

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application